Canadian CANNAINVESTOR Magazine March 2018 | Page 201

MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)

W. Scott Boyes, Chairman, President and CEO

For further information, please contact:

MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)

W. Scott Boyes, Chairman, President and CEO

[email protected]

www.mpxbioceutical.com

Justin Canivet

NATIONAL Equicom

T: +1-416-586-1942

[email protected]

201

Louis Kyron: CCIM David E. Argudo: HC

NOTICE TO READER:

As with all of our Q&A sessions, we were not approached or requested to undertake the Q&A but rather we approach those companies that we feel the timing is right. No compensation of any kind or in any form is ever offered, requested, expected, or received.

___________________________________________________________________________________

CCIM: Nick, thank you for taking time of out of your busy schedule to discuss Emblem.

EMC: Thank you, Louis. It’s my pleasure.

CCIM: As an aside, I just thought I would let you know that I recently attended the two day “Medical Cannabis for Business Professionals” course offered by Durham College. I will touch more on that later but Emblem had a few representatives there from a medical perspective and my takeaway from this course was just how knowledgeable and professional they were.

Let’s get right into it. Emblem has over 8,500 square feet of grow space at your Paris Ontario facility and you have expansion plans that will significantly expand total production capacity to upwards of 17,000 kilograms of dried flower per annum. Can you provide an update on how that expansion is proceeding and its ETA?

EMC: That is correct. Our expansion plans on our Paris Rd. property will add an incremental 15,000 kg per annum of production capacity which will take our total production capacity number to more than 17,000 kg per annum in early 2019. Our cash position is solid and we are funded to complete this initiative. We expect site preparation and construction to commence in the coming months with a view to complete or plans and start cultivating in the new facility in early 2019.

CCIM: The licensing agreement with Dosecann Inc. (“Dosecann”) in which Dosecann will begin developing a range of cannabinoid dosage formulations designed to ensure patients are better able to titrate and administer each dose the exact same way. What is the significance of this not only from the patient and medical/caregiver perspective but also from an investor’s perspective?

EMC: We are investing in dosage formats and formulations that medical/caregivers have familiarity with prescribing and administering. And patients have comfort and familiarity taking. We believe the medical market will move away from prescribing dried flower. Oils, pill formats, gels and sustained release tablets are the future.

Louis Kyron: CCIM David E. Argudo: HC